Efficacy of Standard Meropenem Dosing in Healthcare-Associated Meningitis: Is It Universal?
Authors' conclusion
Overall, a daily dose of 6 g appears sufficient to treat CNS infections caused by E. cloacae, K. pneumoniae, and S. marcescens, whereas none of the dosing regimens tested seem adequate for P. aeruginosa, which more frequently exhibits high MICs > 1 mg/L.
Study context
- Population
- Neuro-ICU patients with external ventricular drains (EVD) receiving meropenem via intermittent or continuous infusions (6–8 g/day)neuro-ICU patients with EVD · confirmed central nervous system (CNS) infection 14 · extra-CNS infection 14
- Participants
- 28 patients
- Comparison
- Patients with confirmed CNS infection to those with extra-CNS infection
- CNS infectionn = 14
- extra-CNS infectionn = 14
- Outcome
- CSF/plasma AUC ratio of meropenem
Methodological detailsMonte Carlo simulations
- Monte Carlo simulations
Main finding
As reported in the abstract
Further findings
Probability of target attainment (PTA) in cerebrospinal fluid (CSF) (Monte Carlo simulation), patients with CNS infection · steady-state
- PTA in CSF with 6 g/d for MIC up to 0.25 mg/L
- > 90%
- PTA in CSF with 8 g/d for MIC of 1 mg/L
- 89.7%
- Target 100% T > MIC
Original publication
Efficacy of Standard Meropenem Dosing in Healthcare-Associated Meningitis: Is It Universal? Anaesth Crit Care Pain Med. Published 6 October 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →